Calithera Biosciences, Inc. (CALA) Cut to Hold at Zacks Investment Research
According to Zacks, “Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company’s lead product candidate includes CB-839 which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. Calithera Biosciences, Inc. is headquartered in South San Francisco, California. “
CALA has been the subject of several other research reports. HC Wainwright started coverage on shares of Calithera Biosciences in a research report on Thursday, January 5th. They issued a buy rating and a $9.00 price objective for the company. JMP Securities reaffirmed a buy rating on shares of Calithera Biosciences in a research report on Thursday, December 1st. Finally, Citigroup Inc. started coverage on shares of Calithera Biosciences in a research report on Tuesday, October 25th. They issued a sell rating for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. Calithera Biosciences currently has a consensus rating of Buy and an average target price of $9.19.
Shares of Calithera Biosciences (NASDAQ:CALA) traded up 6.52% during mid-day trading on Tuesday, hitting $4.90. 315,233 shares of the stock traded hands. The stock has a 50-day moving average of $3.41 and a 200 day moving average of $3.24. The stock’s market cap is $101.61 million. Calithera Biosciences has a one year low of $2.20 and a one year high of $6.87.
COPYRIGHT VIOLATION WARNING: “Calithera Biosciences, Inc. (CALA) Cut to Hold at Zacks Investment Research” was first posted by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was stolen and republished in violation of international trademark & copyright law. The original version of this article can be read at http://www.dailypolitical.com/2017/01/13/calithera-biosciences-inc-cala-cut-to-hold-at-zacks-investment-research.html.
In other news, major shareholder Adage Capital Partners Gp, L.L acquired 500,000 shares of the stock in a transaction on Wednesday, November 16th. The stock was bought at an average price of $3.15 per share, with a total value of $1,575,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 27.50% of the stock is currently owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Paloma Partners Management Co acquired a new position in Calithera Biosciences during the second quarter valued at approximately $150,000. GSA Capital Partners LLP boosted its position in Calithera Biosciences by 25.9% in the second quarter. GSA Capital Partners LLP now owns 43,800 shares of the company’s stock valued at $162,000 after buying an additional 9,000 shares during the period. D. E. Shaw & Co. Inc. boosted its position in Calithera Biosciences by 119.1% in the third quarter. D. E. Shaw & Co. Inc. now owns 81,613 shares of the company’s stock valued at $265,000 after buying an additional 44,364 shares during the period. Franklin Street Advisors Inc. NC boosted its position in Calithera Biosciences by 18.6% in the third quarter. Franklin Street Advisors Inc. NC now owns 100,000 shares of the company’s stock valued at $325,000 after buying an additional 15,700 shares during the period. Finally, Bridgeway Capital Management Inc. boosted its position in Calithera Biosciences by 102.8% in the second quarter. Bridgeway Capital Management Inc. now owns 157,850 shares of the company’s stock valued at $586,000 after buying an additional 80,000 shares during the period. Institutional investors own 40.23% of the company’s stock.
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.